Cellular and humoral immune responses to chimeric EGFP-pseudocapsids derived from the mouse polyomavirus after their intranasal administration

Vaccine

Volumn 26, Issue 26, 2008, Pages 3242-3251

  Frič, Jan ^a,b   Marek, Martin ^a   Hrušková, Veronika ^a   Holáň, Vladimír ^a,b   Forstová, Jitka ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Antigen carrier and adjuvant; Chimeric VLPs; Mouse polyomavirus pseudocapsids

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; FREUND ADJUVANT; GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEASOME; PROTEIN VP1; PROTEIN VP3; RECOMBINANT ENHANCED GREEN FLUORESCENT PROTEIN; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ACIDIFICATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BLOOD; BONE MARROW CELL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ENDOSOME; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; INTERFERON PRODUCTION; LYMPH NODE; MOUSE; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN PROCESSING; REGULATORY T LYMPHOCYTE; SPLEEN; T LYMPHOCYTE; VIRION; VIRUS CAPSID; VIRUS INFECTION; VIRUS LIKE AGENT;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; BLOOD; CAPSID PROTEINS; CELL PROLIFERATION; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GREEN FLUORESCENT PROTEINS; INTERFERON TYPE II; INTERLEUKIN-2; LYMPH NODES; MICE; POLYOMAVIRUS; RECOMBINANT FUSION PROTEINS; SPLEEN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, VIROSOME;

EID: 44749091287     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.006     Document Type: Article

References (35)

1. Bickert T., Wohlleben G., Brinkman M., Trujillo-Vargas C.M., Ruehland C., Reiser C.O., et al. Murine polyomavirus-like particles induce maturation of bone marrow-derived dendritic cells and proliferation of T cells. Med Microbiol Immunol 196 1 (2007 Mar) 31-39
2. Tegerstedt K., Franzen A., Ramqvist T., and Dalianis T. Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor. Cancer Immunol Immunother 56 9 (2007 Sep) 1335-1344
3. Abbing A., Blaschke U.K., Grein S., Kretschmar M., Stark C.M., Thies M.J., et al. Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J Biol Chem 279 26 (2004 Jun 25) 27410-27421
4. Greenstone H.L., Nieland J.D., de Visser K.E., De Bruijn M.L., Kirnbauer R., Roden R.B., et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95 4 (1998 Feb 17) 1800-1805
5. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (2002 Nov 21) 1645-1651
6. Ramqvist T., Andreasson K., and Dalianis T. Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin Biol Ther 7 7 (2007 Jul) 997-1007
7. Gedvilaite A., Frommel C., Sasnauskas K., Micheel B., Ozel M., Behrsing O., et al. Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Virology 273 1 (2000 Jul 20) 21-35
8. Clark B., Caparros-Wanderley W., Musselwhite G., Kotecha M., and Griffin B.E. Immunity against both polyomavirus VP1 and a transgene product induced following intranasal delivery of VP1 pseudocapsid-DNA complexes. J Gen Virol 82 Pt 11 (2001 Nov) 2791-2797
9. Neugebauer M., Walders B., Brinkman M., Ruehland C., Schumacher T., Bertling W.M., et al. Development of a vaccine marker technology: display of B cell epitopes on the surface of recombinant polyomavirus-like pentamers and capsoids induces peptide-specific antibodies in piglets after vaccination. Biotechnol J 1 12 (2006 Dec) 1435-1446
10. Shin Y.C., and Folk W.R. Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor. J Virol 77 21 (2003 Nov) 11491-11498
11. Bouřa E., Liebl D., Spisek R., Fric J., Marek M., Stokrova J., et al. Polyomavirus EGFP-pseudocapsids: analysis of model particles for introduction of proteins and peptides into mammalian cells. FEBS Lett 579 29 (2005 Dec 5) 6549-6558
12. Forstova J., Krauzewicz N., Wallace S., Street A.J., Dilworth S.M., Beard S., et al. Cooperation of structural proteins during late events in the life cycle of polyomavirus. J Virol 67 3 (1993 Mar) 1405-1413
13. Forstova J., Krauzewicz N., Sandig V., Elliott J., Palkova Z., Strauss M., et al. Polyoma virus pseudocapsids as efficient carriers of heterologous DNA into mammalian cells. Hum Gene Ther 6 3 (1995 Mar) 297-306
14. Türler H., and Beard P. Simian virus SV40 and polyomavirus: growth, titration, transformation and purification of viral components. In: Mahy W.J. (Ed). Virology: a practical approach (1985), IRL Press, Oxford, United Kingdom 169-192
15. Zal T., Volkmann A., and Stockinger B. Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen. J Exp Med 180 6 (1994 Dec 1) 2089-2099
16. Gambotto A., Dworacki G., Cicinnati V., Kenniston T., Steitz J., Tuting T., et al. Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Ther 7 23 (2000 Dec) 2036-2040
17. Gedvilaite A., Dorn D.C., Sasnauskas K., Pecher G., Bulavaite A., Lawatscheck R., et al. Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. Virology 354 2 (2006 Oct 25) 252-260
18. Moron V.G., Rueda P., Sedlik C., and Leclerc C. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol 171 5. (2003 Sep 1) 2242-2250
19. Zhang L.F., Zhou J., Chen S., Cai L.L., Bao Q.Y., Zheng F.Y., et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 18 11-12 (2000 Jan 6) 1051-1058
20. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 6 (1995 Jun) 3959-3963
21. Caparros-Wanderley W., Clark B., and Griffin B.E. Effect of dose and long-term storage on the immunogenicity of murine polyomavirus VP1 virus-like particles. Vaccine 22 3-4 (2004 Jan 2) 352-361
22. Kirnbauer R., Chandrachud L.M., O'Neil B.W., Wagner E.R., Grindlay G.J., Armstrong A., et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219 1 (1996 May 1) 37-44
23. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92 25 (1995 Dec 5) 11553-11557
24. Yuan L., Geyer A., Hodgins D.C., Fan Z., Qian Y., Chang K.O., et al. Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs. J Virol 74 19 (2000 Oct) 8843-8853
25. Lenz P., Day P.M., Pang Y.Y., Frye S.A., Jensen P.N., Lowy D.R., et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 166 9 (2001 May 1) 5346-5355
26. Brinkman M., Walter J., Grein S., Thies M.J., Schulz T.W., Herrmann M., et al. Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma. Cancer Immunol Immunother 54 6 (2005 Jun) 611-622
27. Lo-Man R., Rueda P., Sedlik C., Deriaud E., Casal I., and Leclerc C. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol 28 4 (1998 Apr) 1401-1407
28. Sedlik C., Dridi A., Deriaud E., Saron M.F., Rueda P., Sarraseca J., et al. Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses. J Virol 73 4 (1999 Apr) 2739-2744
29. Song S., Wang Y., Zhang Y., Wang F., He Y., Ren D., et al. Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG. Cancer Lett 256 1 (2007 Oct 18) 90-100
30. Strawbridge A.B., and Blum J.S. Autophagy in MHC class II antigen processing. Curr Opin Immunol 19 1 (2007 Feb) 87-92
31. Aandahl E.M., Michaelsson J., Moretto W.J., Hecht F.M., and Nixon D.F. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 78 5 (2004 Mar) 2454-2459
32. Andersson J., Boasso A., Nilsson J., Zhang R., Shire N.J., Lindback S., et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol 174 6 (2005 Mar 15) 3143-3147
33. Boettler T., Spangenberg H.C., Neumann-Haefelin C., Panther E., Urbani S., Ferrari C., et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 79 12 (2005 Jun) 7860-7867
34. Cassan C., Piaggio E., Zappulla J.P., Mars L.T., Couturier N., Bucciarelli F., et al. Pertussis toxin reduces the number of splenic Foxp3+ regulatory T cells. J Immunol 177 3 (2006 Aug 1) 1552-1560
35. Chen X., Winkler-Pickett R.T., Carbonetti N.H., Ortaldo J.R., Oppenheim J.J., and Howard O.M. Pertussis toxin as an adjuvant suppresses the number and function of CD4+CD25+ T regulatory cells. Eur J Immunol 36 3 (2006 Mar) 671-680